Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc (BMRN) Straddle
BMRN straddle scan found 118 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 56.6%.
Read more
Trading a BMRN straddle lets you take a pure volatility position on Biomarin Pharmaceutical Inc without committing to a direction. Biomarin Pharmaceutical Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate BMRN straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on BMRN profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Biomarin Pharmaceutical Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the BMRN straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the BMRN straddle is the cleanest expression of that view. Our scanner prices every BMRN straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a BMRN straddle into a catalyst or short a BMRN straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 19, 2029 | 80.00 | $30.10 | 806 | 31% | 56.6% | $110.10 | $49.90 | 0 |
| Jan 19, 2029 | 85.00 | $33.75 | 806 | 31% | 56.5% | $118.75 | $51.25 | 0 |
| Jan 19, 2029 | 95.00 | $42.15 | 806 | 31% | 55.6% | $137.15 | $52.85 | 0 |
| Jan 19, 2029 | 90.00 | $38.25 | 806 | 31% | 55.4% | $128.25 | $51.75 | 0 |
| Jun 16, 2028 | 85.00 | $32.00 | 589 | 31% | 55.2% | $117.00 | $53.00 | 0 |
| Jun 16, 2028 | 80.00 | $28.30 | 589 | 31% | 55.1% | $108.30 | $51.70 | 80 |
| Jan 21, 2028 | 80.00 | $26.40 | 442 | 31% | 55.0% | $106.40 | $53.60 | 0 |
| Jun 16, 2028 | 77.50 | $26.95 | 589 | 31% | 54.4% | $104.45 | $50.55 | 0 |
| Jan 19, 2029 | 75.00 | $28.25 | 806 | 31% | 54.2% | $103.25 | $46.75 | 0 |
| Jun 16, 2028 | 90.00 | $36.90 | 589 | 31% | 53.8% | $126.90 | $53.10 | 0 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →